MAJIC trial results: ruxolitinib compared to best available therapy for essential thrombocythemia
Myeloma 2016: Panel discussion on the environment biology of myeloma
Dirk Hose et al.
Venetoclax and the future of treatment of multiple myeloma
The benefits of using Twitter as a doctor
Results of the Phase III PERSIST-1 trial of pacritinib for myelofibrosis